Engineering bacteria to treat metastatic colorectal cancer
Engineering S. typhimurium for metastatic colorectal cancer
This study is exploring how specially designed bacteria can help treat metastatic colorectal cancer by making them smart enough to find and attack cancer cells, and it’s aimed at improving treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia Univ New York Morningside NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10733437 on NIH RePORTER |
What this research studies
This research focuses on using genetically engineered bacteria to target and treat metastatic colorectal cancer. By programming these living cells to sense and respond to their environment, the approach aims to enhance the specificity and effectiveness of cancer therapies. The study will utilize a high-throughput platform to rapidly test various therapeutic strategies and assess their impact on different genetic backgrounds of colorectal cancer. Ultimately, the goal is to evaluate the safety and efficacy of these engineered bacteria in mouse models before considering clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who may benefit from innovative therapeutic approaches.
Not a fit: Patients with early-stage colorectal cancer or those not diagnosed with colorectal cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with metastatic colorectal cancer.
How similar studies have performed: Other research has shown promise in using engineered bacteria for cancer therapy, indicating a potential for success in this novel approach.
Where this research is happening
New York, United States
- Columbia Univ New York Morningside — New York, United States (Active)
Researchers
- Principal investigator: Danino, Tal — Columbia Univ New York Morningside
- Study coordinator: Danino, Tal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.